Vismodegib as eye-sparing adjuvant treatment for orbital basal cell carcinoma

JAMA Ophthalmol. 2013 Oct;131(10):1364-6. doi: 10.1001/jamaophthalmol.2013.4430.
No abstract available

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Aged
  • Anilides / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Biopsy
  • Carcinoma, Basal Cell / drug therapy*
  • Carcinoma, Basal Cell / pathology
  • Carcinoma, Basal Cell / surgery
  • Chemotherapy, Adjuvant
  • Hedgehog Proteins / antagonists & inhibitors
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Ophthalmologic Surgical Procedures
  • Orbital Neoplasms / drug therapy*
  • Orbital Neoplasms / pathology
  • Orbital Neoplasms / surgery
  • Pyridines / therapeutic use*

Substances

  • Anilides
  • Antineoplastic Agents
  • Hedgehog Proteins
  • HhAntag691
  • Pyridines